Gestational route to healthy birth (GaRBH):protocol for an Indian prospective cohort study by Gupta, Vipin et al.
                          Gupta, V., Saxena, R., Walia, G. K., Aggarwal, T., Dunn, W. B., Relton, C.
L., ... Sachdeva, M. P. (2019). Gestational route to healthy birth (GaRBH):
protocol for an Indian prospective cohort study. BMJ Open, 9(4), [e025395].
https://doi.org/10.1136/bmjopen-2018-025395
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1136/bmjopen-2018-025395
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via BMJ Publishing at
https://bmjopen.bmj.com/content/9/4/e025395 . Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
1Gupta V, et al. BMJ Open 2019;9:e025395. doi:10.1136/bmjopen-2018-025395
Open access 
Gestational route to healthy birth 
(GaRBH): protocol for an Indian 
prospective cohort study
Vipin Gupta,1 Ruchi Saxena,2 Gagandeep Kaur Walia,3 Tripti Agarwal,3 Harsh Vats,1 
Warwick Dunn,4 Caroline Relton,5 Ulla Sovio,6 Aris Papageorghiou,7 
George Davey Smith,5 Rajesh Khadgawat,8 Mohinder Pal Sachdeva1
To cite: Gupta V, Saxena R, 
Walia GK, et al.  Gestational 
route to healthy birth 
(GaRBH): protocol for 
an Indian prospective 
cohort study. BMJ Open 
2019;9:e025395. doi:10.1136/
bmjopen-2018-025395
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
025395). 
VG, RS and GKW contributed 
equally.
Received 12 July 2018
Revised 17 October 2018
Accepted 12 March 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Vipin Gupta;  
 udaiig@ gmail. com
Protocol
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY. 
Published by BMJ.
AbstrACt
Introduction Pregnancy is characterised by a high rate 
of metabolic shifts from early to late phases of gestation 
in order to meet the raised physiological and metabolic 
needs. This change in levels of metabolites is influenced 
by gestational weight gain (GWG), which is an important 
characteristic of healthy pregnancy. Inadequate/excessive 
GWG has short-term and long-term implications on 
maternal and child health. Exploration of gestational 
metabolism is required for understanding the quantitative 
changes in metabolite levels during the course of 
pregnancy. Therefore, our aim is to study trimester-specific 
variation in levels of metabolites in relation to GWG and 
its influence on fetal growth and newborn anthropometric 
traits at birth.
Methods and analysis A prospective longitudinal study 
is planned (start date: February 2018; end date: March 
2023) on pregnant women that are being recruited in the 
first trimester and followed in subsequent trimesters and 
at the time of delivery (total 3 follow-ups). The study is 
being conducted in a hospital located in Bikaner district 
(66% rural population), Rajasthan, India. The estimated 
sample size is of 1000 mother-offspring pairs. Information 
on gynaecological and obstetric history, socioeconomic 
position, diet, physical activity, tobacco and alcohol 
consumption, depression, anthropometric measurements 
and blood samples is being collected for metabolic assays 
in each trimester using standardised methods. Mixed 
effects regression models will be used to assess the role 
of gestational weight in influencing metabolite levels 
in each trimester. The association of maternal levels of 
metabolites with fetal growth, offspring’s weight and body 
composition at birth will be investigated using regression 
modelling.
Ethics and dissemination The study has been 
approved by the ethics committees of the Department of 
Anthropology, University of Delhi and Sardar Patel Medical 
College, Rajasthan. We are taking written informed consent 
after discussing the various aspects of the study with the 
participants in the local language.
IntroduCtIon 
The profound metabolic changes during 
healthy pregnancy ensure optimum fetal 
development and appropriate nutrient allo-
cation between the mother and fetus.1 2 
Such metabolic adjustments are required for 
meeting raised physiological needs of preg-
nancy and for providing additional energy to 
support labour and lactation.1 The concept 
of ‘the developmental origins of health and 
disease’ suggests that exposures during crit-
ical periods in utero can lead to ‘programmed’ 
structural and/or functional alterations that 
can transmit to the next generation and 
predispose them to disease at later age.3 4 A 
study on 115 women with normal pregnancy 
has found that higher circulating fatty acids 
are associated with lower blood pressure and 
more favourable metabolic phenotype of the 
mothers.5 The disparity in metabolic changes 
during pregnancy may influence fetal growth, 
and can increase the likelihood of adverse 
metabolic profiles across the life-course for 
both mother and the offspring through fetal 
programming.6 For instance, increased trans-
port of glucose and free fatty acids to the 
fetal-placental unit can lead to adverse fetal 
growth (ie, macrosomia).7 8 
The biological system-wide understanding 
of metabolism requires us to capture 
strength and limitations of this study
 ► This is a longitudinal study in India to examine tri-
mester-specific metabolomic changes during the 
course of pregnancy and their influence on fetal 
growth.
 ► The study is collecting biological measurements on 
pregnant women during each trimester (first, second 
and third trimester) and their offspring at the time 
of birth.
 ► Newborns will be intensively phenotyped for the lev-
els of metabolites and body composition.
 ► Unlike other Indian cohorts, the study participants 
are being recruited from a government hospital that 
caters for a rural population.
 ► Lack of information on prepregnancy measurements 
will restrict our analysis to the duration of pregnancy 
only.
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phenotypic changes of the human metabolome, which 
comprises the full spectrum of metabolites present in all 
cells, tissues or fluids of the human body,9–11 in different 
physiological states (ie, puberty, pregnancy, lactation and 
premenopause/postmenopause). The metabolome can 
be considered as an intermediate phenotypic mixture 
of metabolites encoded by our genome, influenced by 
specific environmental exposures and it shapes an indi-
vidual’s metabolic phenotype or metabotype.10–12 It can be 
studied through the holistic approach of metabolomics 
that provides a quantitative fingerprint of all metabo-
lites present in cells, tissues or an organism and can be 
measured using high-throughput technologies.13 14 The 
field of metabolomics is important for uncovering quan-
titative metabolic trajectories of normal and abnormal 
pregnancies. The studies on quantitative estimation of 
longitudinal metabolomic changes during gestation are 
globally few in number15–17 and there are none we know 
of in India.
Metabolomic changes in pregnancy
The incomplete understanding of the complex nature 
of metabolic processes during pregnancy has generated 
considerable interest in exploring the effect of gesta-
tional characteristics on metabolomic changes during 
pregnancy and its impact on offspring health. Hyper-
glycaemia during pregnancy is one of the widely studied 
examples of pregnancy-induced metabolic stress which 
increases maternal risk of type 2 diabetes and also predis-
poses the developing fetus to poor metabolic health.18 
Studies have also assessed the metabolomics of pregnancy 
complications, such as, gestational diabetes,19 20 placental 
abruption21 and birth outcomes, such as preterm birth,22 
small for gestational age23 and large for gestational age.24
An exploratory study has investigated the changes in 
metabolite levels during pregnancy among women with 
gestational diabetes in the third trimester and found 
elevated levels of branched chain amino acids, leucine, 
isoleucine and valine.25 The catabolic nature of third 
trimester is represented by a decrease in maternal 
glucose levels and substantial rise in the levels of fasting 
insulin which in turn can lead to insulin resistance.26 
Moreover, circulating levels of lipids and lipoproteins 
rise twofold to threefold in late pregnancy.27 Maternal 
amino acid levels change longitudinally due to placental 
uptake and fetal transfer from first to third trimesters.15 
There is an increase in energy production through the 
TCA cycle during the course of gestation along with 
concomitant decreases in free carnitine and acetylcar-
nitine and increase in carnitine palmitoyltransferase-1 
activity and β-hydroxybutyrate levels.15 A recent study has 
detected a role for metabolites in fetal sex differences 
in placental complications. It was found that higher 
maternal levels of spermine metabolite N1,N12-diacetyl-
spermine (DiAcSpm), from the first to third trimesters, 
are observed in the female placenta and in the serum of 
women with a female fetus.17
relationships between maternal gestational weight gain and 
newborn health
Gestational weight gain (GWG) is a complex biolog-
ical trait which is influenced by maternal physiology, 
maternal, placental and fetal metabolism.28 There are 
short-term or long-term implications of inadequate 
or excessive GWG which direct the trade-off between 
maternal and child health outcomes.28–32 For example, 
inadequate weight gain is associated with high risks of 
low birth weight, small for gestational age and preterm 
birth.33 Excessive GWG is associated with large for 
gestational age, gestational diabetes, caesarean section 
and postpartum weight retention.34 Furthermore, high 
prepregnancy maternal body mass index (BMI) is associ-
ated with perturbations to maternal metabolome across 
gestation.35
Maternal GWG is a good indicator of fetal nutrition.36 
Any amount of weight gain in the first 14 weeks and 
high rate of weight gain (>500 g/week) in 14–36 weeks 
are associated with raised adiposity in the offspring.37 
GWG in the first trimester is associated with offspring 
BMI from infancy to early childhood whereas excessive 
GWG (ie, ≥500 g/week) in second and third trimesters 
is associated with increased birth weight.38 In the first 
half of the pregnancy (<20 weeks), excessive GWG is 
associated with higher birth weight and high body fat in 
newborns compared with the second half of pregnancy.39 
Furthermore, Gaillard et al40 observed that early GWG 
was associated with increased adiposity levels and adverse 
cardiometabolic profile in childhood independent of 
prepregnancy weight. A study that investigated the effect 
of trimester-specific GWG on newborn anthropometry 
has found that women with an excessive rate of GWG in 
mid/late pregnancy deliver the heaviest babies.41 Thus, 
the role of optimum GWG in fetal and child health is well 
studied42 but the underlying biological mechanisms or 
mediating pathways are as yet unknown. The maternal fat 
deposition in early pregnancy due to excessive GWG may 
lead to maternal dysmetabolism43 44 and effect the levels 
of maternal metabolites in subsequent trimesters. A study 
has found that the levels of triglycerides, high-density lipo-
protein-cholesterol, apolipoprotein A1 and interleukin-6 
are linearly associated with GWG across all levels of GWG 
in mid-pregnancy.37 The authors postulated that mothers 
with high GWG may engage in lifestyles during and after 
pregnancy that may encourage weight gain. However, a 
few Indian studies have incorporated the GWG in their 
analyses, for example, an association of inadequate or 
excessive GWG with preterm deliveries,45 average GWG 
among women with gestational diabetes46 and maternal 
dietary intake of milk protein in first trimester on 
GWG.47 But there is no Indian study that has explored 
the association between GWG and levels of metabolites. 
The continuous variability in the amount of weight gain 
during pregnancy, with respect to parity, height and geog-
raphy,48–50 has motivated the research for detecting the 
predictors and outcomes of GWG.
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Maternal metabolic associations with newborn phenotypes
Maternal prepregnancy obesity can predict higher 
branched chain amino acids and related metabolites 
in offspring.51 The increase in maternal prepregnancy 
BMI is strongly associated with adverse cardiometa-
bolic profile (very low-density lipoprotein [VLDL], 
VLDL-cholesterol, VLDL-triglycerides, VLDL-diameter, 
branched/aromatic amino acids, glycoprotein acetyls 
and triglycerides) in offspring.52 A Mendelian randomi-
sation study has suggested causal relationships between 
genetically elevated maternal prepregnancy BMI (1 SD) 
and blood glucose levels (7.2 mg/dL) with higher birth 
weight (55 g [95% CI: 93 g; p=0.004] and 114 g [95% CI: 
147 g; p=7×10–9], respectively) of the offspring.53 The 
metabolic shift from first to third trimester of gestation 
can influence newborn phenotypes. A large study related 
to the effects of maternal metabolic signatures on fetal 
growth has identified urinary metabolites (like branched-
chain amino acids, isoleucine, valine, leucine, alanine, 
choline, 3-hydroxyisobutyrate, progesterone and oestro-
gens) predictive of fetal growth, and explained 48%–53% 
of total variation in birth weight.16 Recently, a pilot study 
has shown that both gestational age of the pregnancy 
(comparable to that estimated by ultrasound) and risk for 
preterm delivery can be predicted by measuring cell-free 
RNA transcripts in maternal blood during pregnancy.54 
This study highlighted the opportunities offered in the 
identification of non-invasive blood-based biomarkers of 
pregnancy outcome.54 It has been shown that maternal 
hyperglycaemia is associated with higher cord blood 
concentrations of lysophosphatidylcholines in offspring 
independent of lifestyle intervention among obese 
women.55 Thus, maternal prepregnancy BMI, RNA tran-
scripts and hyperglycaemia during gestation influences 
fetal and newborn phenotypes.
Scholtens et al56 assessed the impact of maternal hyper-
glycaemia, measured using an oral glucose tolerance 
test (OGTT), on fetal phenotypes at 28 weeks of gesta-
tion. They observed a decrease in amino acids, fatty 
acids and products of lipid metabolism, whereas a rise 
in triglycerides and carbohydrates was observed between 
fasting and 1 hour OGTT samples. Furthermore, the 
role of maternal glucose, triglycerides and fatty acids in 
predicting the newborn birth weight and sum of skin-
folds thicknesses was also suggested. This confirmed the 
Freinkel modification of the Pedersen hypothesis, that 
is, fetal growth and fat accumulation in the setting of 
maternal hyperglycaemia is contributed to by other nutri-
ents in addition to glucose.57 The longitudinal assessment 
of the role of maternal metabolites during the length of 
the pregnancy on birth outcomes is restricted to four 
studies, of which two studies use urine samples16 58 and 
the remaining two blood samples.15 17
Gestational route to healthy birth cohort study
GWG in first trimester acts as an exposure for the levels 
of metabolites as an outcome in subsequent trimesters. 
Similarly, the levels of metabolites in a trimester can also 
act as an exposure for GWG in next trimester(s). There-
fore, this study aims to quantify differential metabolic 
variability in relation to maternal weight gain during 
pregnancy for assessing its influence, as an exposure, on 
a) fetal growth, b) offspring metabolite levels, c) body 
composition of offspring at birth. The conceptual model 
is given in figure 1. We are asking two research questions:
1. Are quantitative changes in levels of metabolites associ-
ated with GWG during pregnancy?
2. Are quantitative metabolic changes during pregnancy 
associated with fetal growth, offspring levels of metab-
olites and body composition at birth?
study objectives
 ► To detect differential changes in quantitative metab-
olites between the end of the first, second and third 
trimesters of pregnancy and to examine how these 
trajectories are associated with maternal weight gain.
 ► To determine the influence of metabolic changes 
during pregnancy on fetal growth, body composition 
(fat mass, lean mass and bone density) and anthro-
pometry at birth (ie, body length, weight and circum-
ferences) independent of maternal prepregnancy 
BMI and paternal phenotypic characteristics.
 ► To assess the association between maternal metabolic 
profile during pregnancy and metabolite levels of 
offspring at birth (in cord blood).
study area, design and setting
Study area
This study is being conducted in the government 
hospital of Sardar Patel Medical College, that is, 'Prince 
Bijay Singh Memorial Hospital' (PBM), located in the 
subdistrict Bikaner, which is one of the eight subdistricts 
('Tehsils') of Bikaner district in Rajasthan state. According 
Figure 1 Diagrammatic representation of the study 
hypothesis. We assume that the quantitative changes 
in maternal circulating metabolites are associated with 
gestational weight gain, and it influences fetal growth, 
offspring’s levels of metabolites, and body composition and 
anthropometric traits at birth.
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to Census of India,59 Rajasthan is India’s largest state in 
terms of geographical area, with a population size of 68 
million. The population of Bikaner district is 2.3 million 
(66% is rural) of which 47% are females. In Bikaner, 
crude birth rate is 26 per 1000 individuals, the total 
fertility rate is 3 and the infant mortality rate is 60 per 
1000 individuals.60 The majority of study participants are 
homemakers (80%), follow the Hindu religion (70%) 
and approximately 20% of the participants are illiterate. 
The choice of PBM hospital was based on the availability 
of government medical facility, which is the largest in 
district Bikaner and it ensures health care accessibility 
and affordability (due to free of cost treatment) for the 
entire population.
Study design
A hospital-based cohort study which is recruiting and 
longitudinally following the pregnant women until 
delivery, and their offspring at birth in district Bikaner, 
Rajasthan, India.
Sample size
Studies of fairly large size for detecting associations 
between longitudinal changes in levels of metabolites in 
pregnancy and fetal growth, and levels of metabolites of 
the offspring at birth, are few in number. For example, 
Ciborowski et al61 used 770 samples collected during 
the first trimester for studying the relationship between 
maternal metabolic levels with macrosomia and low birth 
weight. Maitre et al58 investigated 34 metabolites on 438 
samples recruited during the first trimester and found 
an association with fetal growth restriction and preterm 
birth. The majority of studies related to metabolic 
changes during pregnancy62–64 and maternal-fetal medi-
cine65 66 were based on 30–60 samples.67 68 Exact power 
calculations are challenging due to a restricted number 
of prior studies leading to unknown features.69 Even the 
largest study on 4212 participants for studying the predic-
tive metabolomic biomarker for placental complications 
included limited sample of pre-eclampsia (n=134), fetal 
growth restriction (n=162) and controls (n=259).17 Thus, 
the proposed sample size must be larger than the majority 
of informative studies conducted to date and feasible 
within the cost boundaries for the technology being used.
Tynkkynen et al70 studied quantitative urine and serum 
metabolite data on 995 samples of Northern Finland 
Birth Cohort for establishing the proof of concept for 
conducting large-scale epidemiological studies in metab-
olomics using an example of BMI. A relatively large study 
(n=800) has found that maternal urine metabolites can 
independently explain 12% of birth weight after adjusting 
for all other lifestyle/clinical factors.16 They also found 
an association of trimester-specific metabolic changes on 
fetal weight (change of 1.2% in first trimester and 2.4% in 
third trimester). Studies have observed that a metabolite 
level may change from 10% to 30% (even more for some 
metabolites) from first trimester to third trimester.15 71
For a cross-sectional analysis, a sample size of 1000 will 
be sufficient (with 98% power) to explain 4%–5% varia-
tion in the level of a metabolite by maternal weight as a 
predictor, even after correcting for multiple testing (α= 
0.0001; for number of metabolites). Moreover, a sample 
size of 1000 will also be sufficient to explain 2% varia-
tion in the fetal growth parameters (with 80% power, 
α=0.0001) by maternal level of metabolite as a predictor.
Therefore, we propose to recruit 2500 pregnant women 
during the first trimester in order to measure metabolites 
on at least 1000 pregnant women (we may recruit >1000 
women) in each trimester and their offspring, accounting 
for loss to follow-up.
recruitment strategy
Women visiting the antenatal clinic of the PBM hospital 
are being screened with the help of a one-page question-
naire to assess their eligibility for the study. We aim to 
screen around 6000 pregnant women from PBM hospital 
to reach the targeted sample size. The participants will 
have to satisfy the eligibility criteria (given below) before 
being recruited at baseline (figure 2) from February 2018 
to March 2023:
1. 10 weeks of gestation;
2. Age: ≥18 to <35 years;
3. Singleton pregnancy;
4. Natural conception (ie, without any fertility treat-
ment);
5. No long-term medication (ie, not more than 2 weeks 
in last 1 year);
6. No more than one miscarriage in previous pregnan-
cies. In cases where the current pregnancy is the sec-
ond pregnancy, then the women with miscarriage in 
their first pregnancy will also be excluded;
7. No previous pregnancy affected by pre-eclampsia/ec-
lampsia;
8. No clinical evidence of sexually transmitted disease;
9. No hormonal therapy.
We will not exclude the study participants (recruited 
in first trimester) who develop pregnancy complications 
Figure 2 Recruitment and follow-up strategy being used in 
GaRBH cohort.
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in subsequent trimesters that may influence fetal growth 
(like pre-eclampsia,72 eclampsia, intrauterine growth 
restriction and gestational diabetes mellitus73). Exclu-
sion of these complications in current pregnancy would 
lead to a reduction in the natural variation in the study 
population. Furthermore, we will not exclude preterm 
delivery cases due to its relationship with fetal growth74 
and its high burden (ie, 12.8 million in 2010) in India,75 
as it could lead to bias by restricting the sampling to very 
healthy pregnancies which may not represent the general 
population.
Patient and public involvement
The fieldworkers are trained to establish rapport with 
the study population, which begins with describing the 
research questions and objectives of the study to the preg-
nant women visiting the antenatal clinic of PBM hospital 
during first trimester. Once they agree to consider partic-
ipation, project staff discusses the participant informa-
tion sheet, containing detailed information on all the 
measures and outcomes of the project with them in local 
language. Our data collection process starts only after 
taking the informed written consent from the eligible 
participants. We constantly try to involve them during 
the pregnancy by providing the readings of biochemical 
parameters and ultrasounds in each trimester and facil-
itate their antenatal visits in PBM hospital. The project 
staff will also provide support to the participant during 
and after the childbirth in the hospital. Moreover, the 
study population will be engaged through public events 
for the final dissemination of the study results.
AssEssMEnt ProCEdurEs And InstruMEntAtIon
ultrasound measures
For ultrasound-based measurements relating to fetal 
growth, we are using the existing standard operating 
procedures described by INTERGROWTH study76 to 
ensure reliable data collection. The data are being 
collected by trained sonographers in Bikaner, who 
are highly familiar with the equipment (SonoACE R7 
Samsung Healthcare) and experienced in conducting 
ultrasound examinations. The intraobserver variation 
will be assessed by repeat sonographic measurements on 
10 participants on the same day. Comparisons will also 
be made between the readings of two sonographers of 
the hospital on 10 participants to assess interobserver 
variability. The interequipment variation in ultrasound 
measures will be assessed by comparing the PBM results 
of 10 participants with the radiology laboratory outside 
the hospital. We will measure the crown-rump length 
(CRL), biparietal diameter, occipitofrontal diameter, 
head circumference, femur length, anterior-posterior 
abdominal diameter. Gestational age based on CRL and 
fetal weight will be estimated with the help of INTER-
GROWTH equations.76 77
Estimation of gestational age
The accurate estimation of individual-level gestational age 
during pregnancy is vital for interpreting fetal anatomy 
and growth patterns and predicting the date of delivery. 
Gestational age is being calculated from the first day of 
the last menstrual period (LMP). Moreover, for women 
providing clear information on LMP (in completed weeks 
and days) their gestational age is being confirmed with 
an ultrasound-based measurement of CRL in the first 
trimester, using an internationally recognised chart.76 If 
the difference between the CRL and LMP estimates is 
≤7 days, LMP is being considered valid and taken as the 
true biological date.76 In women with an LMP and CRL 
difference of >7 days, CRL is being considered valid for 
estimating the gestational age.78
Questionnaires
A comprehensive questionnaire has been developed for 
collecting information on demographic, anthropolog-
ical (caste, religion and consanguinity), medical disease 
history, tobacco and alcohol intake and passive smoking. 
The validated food frequency questionnaire of 'Indian 
Migration Study' is being used for evaluating dietary 
intake.79 Maternal physical activity during pregnancy is 
being assessed using the international physical activity 
questionnaire (ie, 7 days long).80–82 The assets-based tool 
of National Family Health Survey-4 is being used to eval-
uate socioeconomic position.83 For assessing depression, 
we are using the Patient Health Questionnaire84 and 
Edinburgh Postnatal Depression scale.85 The WHO-5 
questionnaire is being used for collecting information on 
quality of life.86 The capability well-being, that is, individ-
ual’s freedom to function in five key areas of their life: 
'stability', 'attachment', 'achievement', 'autonomy' and 
'enjoyment', is being assessed by using the ICEpop CAPa-
bility measure for Adults.87–89 Information on maternal 
environment, gynaecological and obstetrics history is 
also being collected using tools adapted from INTER-
GROWTH study.90 91 Additionally, a structured ques-
tionnaire on social factors like relationships with family 
members, husband position in household, social support 
during pregnancy and travel is being used for assessing 
the quality of social life and adequacy of social support 
(table 1).
Adult anthropometry
The assessment of anthropometric traits (weight, 
height, sitting height, circumferences and skinfolds) are 
being performed on study participants using standard 
procedures.92
Weight is being measured when the participant 
standing straight on the centre of the weighing machine 
(Tanita, model-HD380), arms hanging freely with 
minimum clothes and without accessories. Height is 
being measured as the vertical distance between vertex 
(highest point on head) and floor when the participant 
standing straight with feet together on the level floor 
without footwear, arms resting by the side, with head in 
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eye-ear plane (Frankfort horizontal plane) and heels, 
buttocks and shoulders projected on the vertical plane 
using a wall-mounted stadiometer (ADE, Germany, 
model-MZ10023-3). Sitting height is being measured as 
the maximum distance from the vertex (top of the head) 
to the base of a flat sitting surface, with legs hanging freely 
and head in eye-ear plane.
Circumferences are being measured at the specific land-
marks when the plane of the tape (ADE, model-MZ10021) 
is perpendicular to the long axis of the body and parallel to 
Table 1 Measures, tools and time points of data collection
Mother
OffspringFirst trimester Second trimester Third trimester
Timing of data collection 10th to 13th weeks 22nd to 24th weeks 32nd to 34th weeks Birth
Gynaecological and obstetric ✔ ✔ ✔ – 
Socioeconomic position ✔ ✔ ✔ – 
Anthropological (caste and religion) ✔ ✔ ✔ – 
Education ✔ ✔ ✔ – 
Marital status ✔ ✔ ✔ – 
Smoking ✔ ✔ ✔ – 
Alcohol drinking ✔ ✔ ✔ – 
Medication ✔ ✔ ✔ – 
Disease history ✔ ✔ ✔ – 
Maternal environment ✔ ✔ ✔ – 
Physical activity (IPAQ) ✔ ✔ ✔ – 
Time-activity pattern ✔ ✔ ✔ – 
Food frequency ✔ ✔ ✔ – 
Dietary recall (3 days) ✔ ✔ ✔ – 
PHQ-12 ✔ ✔ ✔ – 
Well-being (WHO-5) ✔ ✔ ✔ – 
Depression (EPNDS) ✔ ✔ ✔ – 
Social factors ✔ ✔ ✔ – 
Capability well-being (ICECAP-A) ✔ ✔ ✔ – 
Anthropometry
  Height/body length ✔ ✔ ✔ ✔
  Sitting height ✔ ✔ ✔ – 
  Weight ✔ ✔ ✔ ✔
  Circumferences ✔ ✔ ✔ ✔
  Skinfolds ✔ ✔ ✔ ✔
Blood pressure ✔ ✔ ✔ – 
  Laboratory tests:
  Glucose, insulin, Hb, lipids, LFT and 
KFT and blood group
✔ ✔ ✔ ✔
Metabolomic data ✔ ✔ ✔ ✔
  Ultrasound measures:
  CRL, BPD, OFD, HC, FL, AC and APAD
✔ ✔ ✔ – 
Placenta and cord measures and images – – – ✔
Body composition (DXA scan) – – – ✔
APAD, anterior-posterior abdominal diameter; BPD, biparietal diameter; CRL, crown-rump length; EPNDS, Edinburgh Post Natal Depression 
Scale; FL, femur length; HC, head circumference; ICECAP-A, ICEpop CAPability measure for Adults; IPAQ, International Physical Activity 
Questionnaire; KFT, kidney function test; LFT, liver function test; OFD, occipitofrontal diameter; PHQ, Psychological health Questionnaire.
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the floor without tape being pulled too loose or too tight. 
Waist circumference is being measured at the narrowest 
point (which is an approximate midpoint) around the 
waist between the lower rib margin of the last palpable rib 
and the top of the iliac crest with the help of a measuring 
tape. Mid-upper arm circumference is being measured at 
the midpoint between the tip of the shoulder and the tip 
of the elbow (acromion and olecranon process, respec-
tively) taken horizontally (at the middle of the biceps). 
Hip circumference is being measured at the widest part of 
the hip (buttock) at the level of the trochanterion, which 
is the most superior point on the greater trochanter of the 
femur, not the most lateral point. Calf circumference is 
being measured on the right leg as the maximum circum-
ference in a plane perpendicular to the long axis of the 
calf until the greatest circumference is located when foot 
is placed on raised platform.
Skinfold measurements are being taken in relaxing 
muscles by grasping a distinct fold that separates from 
underlying muscles with the help of Harpenden Skinfold 
calliper when the jaws of the calliper are perpendicular 
to the length of the fold on the site of measurement. 
Skinfold measurements at biceps, triceps, subscapular, 
suprailiac, medial calf and anterior thigh are being taken 
to the nearest 0.1 mm.
Three readings are being taken for all the anthropo-
metric measures with minimum acceptable difference of 
100 g, 5 mm, 5 mm and 2 mm between the readings for 
weight, height, circumferences and skinfolds, respectively. 
The readings are being recorded to the last completed 
grams or millimetre.
Infant anthropometry
We will use the protocol of the International Fetal 
and Newborn Growth Consortium93 for measuring the 
infants. Birth weight will be taken within 30 min of 
delivery, without clothes and in stable condition when 
the infant is placed an electronic weighing scale (ADE, 
model-M114600) to the nearest 5 g. Infant length will be 
measured within 12 hours of birth using the baby length 
measuring board (ADE range 100–1000 mm), which 
has a fixed headboard and moveable footboard, placed 
on a raised flat platform on the level surface. The head 
of the infant will be positioned in eye-ear plane on the 
board and holding the infant’s legs with the left hand 
and moving the footboard with the right hand. Head 
circumference will be measured when the infant is on 
the lap of the field investigator, with stable head, using 
a measuring tape (SECA, 212) anchored just above the 
eyebrows on the forehead, and at the back the tape 
being positioned over the fullest protuberance of the 
skull. Three readings will be taken for all the newborn 
anthropometric traits with minimum acceptable differ-
ence of 10 g, 5 mm and 2 mm between the readings for 
weight, infant length and circumferences, respectively. 
The readings will be recorded to the last completed 
millimetre.
All the equipment used for the assessment of adult and 
infant anthropometric traits is being calibrated twice a 
week with the help of standard weights and measures.
blood pressure
Maternal blood pressure is being measured in the sitting 
position during each trimester after a rest of 5 min before 
taking the first reading, using an Omron blood pres-
sure monitor (model: HBP-1300) validated for pregnant 
women94 and cuff of appropriate size. Three readings will 
be taken with 2 min interval between the readings with 
maximum acceptable difference of 5 mm Hg between two 
readings. The equipment used is being calibrated thrice a 
week with the readings of mercury sphygmomanometer.
biological sample collection and storage
A 15 mL of blood sample is being collected during each 
trimester from the study participants after overnight 
fasting (10 hours). We are using EDTA-coated, sodium 
fluoride-coated and plain tubes for blood collection 
for the separation of EDTA plasma, fluoride plasma 
and serum samples, respectively. Serum will be used 
for determining the levels of metabolites in addition to 
triglycerides, cholesterol, lipids, kidney function test 
(KFT), liver function tests (LFT) and insulin, whereas 
fluoride plasma will be used for measuring glucose levels. 
EDTA tube is centrifuged at 3500 rpm for separating 
the white blood cells (WBCs) (buffy coat), plasma and 
red blood cells. After separating the plasma, EDTA tube 
containing WBCs will be stored for future extraction of 
DNA for genetic and epigenetic studies. Multiple aliquots 
of serum and plasma collected at each trimester are being 
stored in a −80°C freezer (table 2).
We will collect cord blood and placenta at the time 
of delivery (table 2) and processed with the help of the 
standard operating procedure used in the 'Avon Longitu-
dinal Study of Parents and Children', University of Bristol, 
UK. The cord blood will be collected in EDTA-coated, 
heparin-coated and plain tubes (10 mL each) and these 
will be processed for the separation of plasma and serum. 
The remaining sample in EDTA tube with buffy coat will 
be stored in a freezer at −80°C. In order to stabilise the 
gene expression, RNAlater will be added in heparin tube. 
Placenta will be processed immediately after delivery and 
aliquots of tissue sample from maternal and fetal sides, 
cord tissue and membrane will be stored in a freezers 
at −80°C (table 2). All the stored aliquots will be appro-
priately bar-coded, stored independently in a separate 
storage box.
Laboratory tests
The fasting serum samples will be transferred to the 
Department of Anthropology, University of Delhi, on 
dry ice for the generation of data on biochemical assays 
on all the mothers during each trimester and also on 
their offspring using cord blood. The available auto-an-
alyzer (XL-640, ERBA Mannheim, Czech Republic) in 
the Department of Anthropology, University of Delhi, 
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India, will be used for biochemistry data generation (ie, 
glucose, insulin, lipids, KFT and LFT) after ensuring daily 
calibration. Insulin levels will be estimated using ELISA 
kits. Furthermore, a reagent lot calibration will also be 
performed whenever there is a change in lot number of 
the reagents to estimate the variation in assays between 
two reagent lots. For internal quality control, one blank 
per 100 samples and one control sample from UK National 
External Quality Assessment Service of known concentrations 
will be run in every 200 samples. Moreover, one dupli-
cate and one sample of known concentration from the 
previous batch will be run per 100 samples for assessing 
intra-assay and inter-assay variation, respectively, to help 
with analyses in confirming repeatability and reproduc-
ibility of biochemistry data. Finally, 5% of the samples will 
be run in a different laboratory for all the biochemical 
assays as a measure of external quality control. Moreover, 
information on participant’s blood group, Sickle hemo-
globin (HbS)and HIV infection, which are the part of 
standard protocol of the hospital’s antenatal care, will be 
taken from PBM Hospital.
Quantitative metabolomics
The quantitative data on the level of metabolites (in 
mothers during each trimester and in offspring using cord 
blood) will be generated through a targeted approach for 
screening the predefined and known metabolites using 
a commercial assay, that is, AbsoluteIDQ p400 HR kit 
(Biocrates Life Sciences, Innsbruck, Austria). It provides 
data on 400 endogenous metabolites from 11 metabolite 
classes (ie, amino acids, biogenic amines, monosaccha-
rides, acylcarnitines, diglycerides, triglycerides, lysophos-
phatidylcholines, phosphatidylcholines, sphingomyelins, 
ceramides and cholesteryl esters). The choice of Absolu-
teIDQ p400 HR kit based on proven utility of its previous 
version of kit (AbsoluteIDQ p180) in several metabolo-
mics-based epidemiological studies.9 95–98 Our collabo-
rator, the Phenome Centre Birmingham, University of 
Birmingham, UK, has experience of using this kit in an 
interlaboratory trial. For generating data on targeted 
metabolites, a triple quadrupole mass spectrometry-based 
technology will be used which characterises a metabolite 
by its molecular mass, its specific fractionation pattern 
(tandem mass spectrometry) and high sensitivity.99 The 
complete analytical process will be performed using the 
MetIQ software package, which is an integral part of these 
kits. The quality control procedure used by Suhre et al100 
will be followed for generation and cleaning of metab-
olomic data. One reference sample will be measured 
three times on each plate across the samples. The quality 
of metabolite data will be controlled by estimating their 
coefficient of variation and missing value rates.15 Outlying 
samples and data points will be excluded and finally all 
missing values will be imputed.101
body composition
The body composition of infants will be measured using 
a DXA machine (Osteo Pro Max, BM Technology, Korea) 
Table 2 Type and number of aliquots of biological samples
Pregnancy
OffspringFirst trimester Second trimester Third trimester
Blood samples
  Serum Six aliquots Six aliquots Six aliquots –
  EDTA plasma Two aliquots Two aliquots Two aliquots – 
  Fluoride plasma Two aliquots Two aliquots Two aliquots – 
  Buffy coat One aliquot One aliquot One aliquot – 
Cord blood samples
  Serum – – – Four aliquots
  EDTA plasma – – – Three aliquots
  Heparin plasma – – – Three aliquots
  Buffy coat with RNAlater – – – One aliquot
  Buffy coat – – – One aliquot
Placenta samples
  Maternal side tissue – – – Eight aliquots
  Maternal side tissue with 
RNAlater
– – – Four aliquots
  Fetal side tissue – – – One aliquot
  Fetal side tissue with RNAlater – – – One aliquot
  Membrane tissue – – – One aliquot
  Cord tissue – – – One aliquot
  Cord tissue with RNAlater – – – One aliquot
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available in PBM Hospital, Bikaner. The machine will be 
calibrated using infant phantoms at regular intervals. We 
have developed a standard operating procedure with the 
help of published literature102–104 for neonatal scans of 
femur, spine and whole body. Newborns will be measured 
within 48 hours of delivery after feeding in a calm or 
sleeping state. Infants will be swaddled in a thin cotton 
blanket in the required position and measurement will be 
taken without any metals, buttons or pins on the infant. 
The region of interest (ROI) for anterior-posterior spine 
will be five vertebral bodies of the lumber region; for 
femur scan this will include the femoral neck, trochanters, 
intertrochanteric and total hip regions. For the whole 
body scan, the infant will be positioned at the centre of 
the table, aligned in a straight line from the nose, centre 
of the body and down through the knees and toes. Six 
ROIs will be taken for the whole body scan (head, entire 
right and left arms, right and left leg regions and trunk).
data capture, protection and management
The data are being recorded in paper-based question-
naires that will be initially entered in Microsoft Excel, 
and later transferred to a SQL-based database to be devel-
oped in collaboration with the University of Bristol, UK. 
The master data will be stored at multiple locations (at 
least two) and managed in computers available in the 
Department of Anthropology, University of Delhi. One 
unique identification number (UID) is being assigned 
to each study participant (mothers) that will be common 
for her questionnaire-based information, biological 
measurements, blood and other biological samples. 
Similarly, newborns will also be assigned a UID which 
is linked to the UID of mothers. The computers will be 
password protected, and UID linked with personal iden-
tifiers necessary for contact and future follow up, will be 
encrypted and held separately in a different system and 
backed up regularly. All the biological samples will be 
collected in pre-assigned bar-coded tubes and vials and 
will be stored at −80°C in Bikaner, Rajasthan. A compre-
hensive data dictionary will be prepared for all the study 
variables and the entire data will be regularly checked for 
outliers, distribution of variables and missingness.
data analyses
The evaluation of cross-sectional associations of maternal 
body weight with quantitative metabolite levels in each 
trimester, independently, will be done using regres-
sion-based modelling. Both level of metabolites and gesta-
tional weight in each trimester will act as exposure as well 
as outcome. Variables like socioeconomic position, gesta-
tional age, parity, diet, smoking and physical activity will 
be considered as confounders. Maternal characteristics 
will be considered as exposures (like trimester-specific 
weight, metabolite levels) to evaluate their association 
with offspring-related outcomes (fetal growth, birth 
weight, body compositions and metabolite levels). The 
potential confounders for maternal-offspring associations 
will be socioeconomic position, gestational age, parity, 
diet, sex of the offspring, smoking and physical activity.
Mixed effects regression models for repeated measures 
will be applied for examining longitudinal associa-
tions of weight gain from first to third trimester42 with 
maternal levels of metabolites during pregnancy and fetal 
growth.105 We will also analyse the associations of level 
of metabolites from first to third trimester with trajecto-
ries of GWG. Mediation analyses will be conducted for 
evaluating the role of maternal metabolites as intermedi-
ates between GWG and offspring’s body composition.106 
False discovery rate based multiple testing correction for 
number of metabolites will be applied.107 Mediation anal-
ysis will be conducted to examine whether the effect of 
GWG on fetal growth is mediated through alteration in 
levels of circulating metabolites.
Public health implications
In India, higher prevalence of both malnutrition and over-
nutrition,108 109 increased rates of gestational diabetes110 
and pre-eclampsia111 are common challenges related 
to maternal-fetal health. Moreover, India has high rates 
of birth defects, that is, over 60 per 1000 live births,112 
higher number of infants born small for gestational age,75 
still births113 and >45% of children under 5 years of age 
are stunted,114 which need to be addressed through trans-
lational research. The metabolomic approach will enable 
the identification of biochemical markers predictive for 
undesirable birth outcomes.
The role of the intrauterine environment, through 
fetal overnutrition, has been proposed in considering 
determination of higher birth weight, childhood obesity, 
impaired glucose tolerance and dyslipidemia.115–117 The 
knowledge of trimester-specific quantitative levels of 
metabolites will uncover mechanistic pathways relevant 
for optimum fetal growth and healthy birth outcomes. 
Understanding of changes in gestational metabolism 
will provide many opportunities for detecting potentially 
relevant metabolites for planning effective interventions 
during pregnancy.
Ethics and dissemination
We are taking written informed consent after discussing 
the various aspects of the study with the participants in the 
local language. The findings of the study will be dissem-
inated through peer-reviewed national and international 
journals and through conferences and seminars.
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